DEA Finalizes Cannabis Rescheduling to Schedule III, but Equity Risk Remains

Rescheduling Mechanics and Effective Date

The final rule takes effect 60 days after Federal Register publication, placing the operational start date in late August 2026. According to the DEA's notice, marijuana and marijuana-derived products remain controlled substances under the Controlled Substances Act but move to the same classification tier as ketamine, anabolic steroids, and Tylenol with codeine. Rescheduling doesn't legalize recreational or medical cannabis at the federal level. Possession, distribution, and cultivation outside state-licensed frameworks remain federal crimes.

The Justice Department initiated the review in October 2024 following a Health and Human Services recommendation. The DEA held a public comment period and an administrative law judge hearing before issuing the final rule. No further legal challenges are pending as of June 25, 2026.

280E Tax Relief: The Bull Case

Rescheduling removes Internal Revenue Code Section 280E, which has blocked cannabis operators from deducting ordinary business expenses since 1982. Multi-state operators have reported effective tax rates between 60% and 75% under 280E. Curaleaf, Trulieve, and Green Thumb Industries each carry deferred tax assets exceeding $200 million on their balance sheets—assets that become realizable once 280E no longer applies.

The tax change improves EBITDA-to-free-cash-flow conversion immediately. Analysts at Cowen estimate the average MSO will see a 15-20 percentage-point margin expansion in fiscal 2027. That's real cash. Not accounting fiction. For operators carrying debt at 10-12% coupons, the margin relief could fund deleveraging or expansion without dilutive equity raises.

The math on 280E relief is straightforward:

• Pre-rescheduling: $100M revenue, $40M COGS, $30M opex → $30M taxable income at 21% federal rate = $6.3M tax, but 280E disallows the $30M opex deduction → taxable income becomes $60M → $12.6M tax.
• Post-rescheduling: $100M revenue, $40M COGS, $30M opex → $30M taxable income → $6.3M tax. The operator keeps an extra $6.3M in cash annually.

Federal Prohibition Persists: The Bear Case

Schedule III classification doesn't grant cannabis operators access to interstate commerce, federal banking beyond limited SAFE Banking protections, or Nasdaq uplisting without further legislative action. The Controlled Substances Act still criminalizes marijuana distribution. Operators remain confined to state-by-state licensing regimes, and the FDA retains authority to regulate cannabis as a drug, which could impose costly clinical-trial and labeling requirements.

Institutional investors—pension funds, mutual funds, sovereign wealth vehicles—remain restricted by federal illegality clauses in their investment mandates. A Schedule III designation doesn't change the compliance calculus for a Vanguard or BlackRock index fund. Until the Controlled Substances Act removes cannabis entirely or Congress passes enabling legislation like the SAFE Banking Act or the MORE Act, institutional capital stays sidelined.

Equity performance reflects this uncertainty. The AdvisorShares Pure US Cannabis ETF (MSOS) has declined 62% from its February 2021 peak despite state-market revenue growing 12% annually. The discount to intrinsic value persists because the risk premium hasn't compressed.

Comparable Multiples and Valuation Context

Top-tier MSOs trade at 5-7x forward EBITDA, a 40-50% discount to alcohol distributors and a 60% discount to pharmaceutical wholesalers. Curaleaf trades at 5.2x 2027E EBITDA. Trulieve, the Florida market leader, trades at 6.1x. By contrast, Constellation Brands trades at 11x and AmerisourceBergen at 13x. The valuation gap reflects federal illegality risk, limited institutional ownership, and capital-markets access constraints.

If rescheduling compresses the risk premium by 200 basis points and allows a re-rating to 8-9x EBITDA, the sector could see 40-60% upside from current levels. That's the bull case. Bear case? Federal prohibition persists indefinitely, state markets saturate, and operators remain subscale and capital-starved.

What Investors Should Watch Next

Three variables will determine whether rescheduling translates into equity performance: FDA rulemaking, congressional action on SAFE Banking, and state-market consolidation dynamics. The FDA has 180 days from the effective date to issue guidance on cannabis regulation under Schedule III. If the agency imposes pharmaceutical-grade manufacturing standards or requires clinical trials for product claims, compliance costs could offset 280E savings.

On the legislative front, the SAFE Banking Act has passed the House seven times but stalled in the Senate. A standalone banking bill would unlock commercial lending and payment processing, reducing the sector's reliance on expensive private debt. Without it, operators remain dependent on high-cost credit facilities and dilutive equity.

State-market consolidation is accelerating. Smaller operators without balance-sheet cushion will struggle as margins compress in mature markets like Colorado and Oregon. Top five MSOs control 35% of the U.S. market; that figure could reach 50% by 2028 if capital access remains constrained for mid-tier players.

For full background on the administrative process and timeline, see the CannIntel topic hub on DEA rescheduling.